Centene Corporation (NYSE: CNC) and Washington University School of Medicine in St. Louis announced today a partnership to transform and accelerate research into treatments for Alzheimer’s disease, breast cancer, diabetes and obesity. All are common, debilitating and often deadly diseases that affect millions of people worldwide, at all levels of income.
As part of the partnership, Centene will fund up to $100 million over 10 years in research at Washington University. The funding will galvanize the School of Medicine’s Personalized Medicine Initiative, which aims to develop customized disease treatment and prevention for patients. Innovations that arise from the initiative will be commercialized through the ARCH Personalized Medicine Initiative, a joint venture between the School of Medicine and Centene. Reflecting the philosophy of both institutions, ARCH is designed to accelerate the development and implementation of affordable and accessible health solutions to the public using the intellectual property developed from this research.
“We share the goal of helping to improve the health of our communities through research, education and customized treatment for people suffering from chronic illnesses,” said Michael F. Neidorff, chairman and CEO for Centene. “We believe personalized medicine is the path to ensure patients get the targeted health care they need to fight disease, and we look forward to partnering with such a renowned medical school to initially focus on four diseases that impact millions of Americans, including many of our health plan members.”
The investment will leverage the university’s cutting-edge research and biomedical capabilities, including state-of-the-art technologies such as CRISPR, and internationally known scientists in the areas of the microbiome, immunomodulatory therapies, cancer genomics, neurodegeneration, cellular reprogramming, chemical biology, informatics and others. In addition, the funds will strengthen resources at more than a dozen centers and institutes at the School of Medicine, including the Edison Family Center for Genome Sciences & Systems Biology; the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; the Elizabeth H. and James S. McDonnell III Genome Institute; the Institute for Informatics; and the Center of Regenerative Medicine.
“We will be bringing together world-class resources and intellectual horsepower from every basic and clinical scientific discipline to urgently accelerate the timeline for developing therapies that are more precisely targeted, with aspirations to do so in the next five to seven years,” said David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean, and the Spencer T. and Ann. W. Olin Distinguished Professor at the School of Medicine. “I believe the most important advances that will evolve from the personalized medicine paradigm will come from harnessing genome engineering technologies to build better model systems of each human disease, and utilizing deep genomic and clinical characterization to enable more effective and less expensive clinical trials.”
Perlmutter continued, “The partnership supports our global leadership in understanding sequence variants in biological systems that will pave the way for new therapeutic targets, as well as learning more about our own innate biology. Once personalized medicine becomes common practice, health-care workers may examine each patient’s genome — as well as information regarding his or her environment, lifestyle and social network — to identify a customized, affordable approach to optimizing health and medical care.”
Centene and Washington University will host a press briefing at a later date to be determined.
About Centene Corporation
Centene Corporation, a Fortune 100 company, is a diversified, multi-national healthcare enterprise that provides a portfolio of services to government sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Many receive benefits provided under Medicaid, including the State Children’s Health Insurance Program (CHIP), as well as Aged, Blind or Disabled (ABD), Foster Care and Long-Term Services and Supports (LTSS), in addition to other state-sponsored programs, Medicare (including the Medicare prescription drug benefit commonly known as “Part D”), dual eligible programs and programs with the U.S. Department of Defense. Centene also provides healthcare services to groups and individuals delivered through commercial health plans. Centene operates local health plans and offers a range of health insurance solutions. It also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health management, care management software, correctional healthcare services, dental benefits management, commercial programs, home-based primary care services, life and health management, vision benefits management, pharmacy benefits management, specialty pharmacy and telehealth services.
Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene’s investor relations website, http://www.centene.com/investors.
About Washington University School of Medicine in St. Louis
Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.
Cautionary Statement on Forward-Looking Statements
All statements, other than statements of current or historical fact, contained in this communication are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “seek,” “target,” “goal,” “may,” “will,” “would,” “could,” “should,” “can,” “continue” and other similar words or expressions (and the negative thereof). We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and Centene Corporation is including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about Centene’s future operating or financial performance, market opportunity, growth strategy, competition, expected activities in completed and future acquisitions, including statements about the impact of Centene’s proposed acquisition of WellCare Health Plans, Inc. (the “WellCare Transaction”), Centene’s recent acquisition (the “Fidelis Care Transaction”) of substantially all the assets of New York State Catholic Health Plan, Inc., d/b/a Fidelis Care New York (“Fidelis Care“), investments and the adequacy of Centene’s available cash resources.
These forward-looking statements reflect Centene’s current views with respect to future events and are based on numerous assumptions and assessments made by us in light of Centene’s experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors Centene believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause Centene’s or its industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions.
All forward-looking statements included in this filing are based on information available to us on the date of this communication. Except as may be otherwise required by law, Centene undertakes no obligation to update or revise the forward-looking statements included in this communication, whether as a result of new information, future events or otherwise, after the date of this filing. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to, the following: (i) the risk that regulatory or other approvals required for the WellCare Transaction may be delayed or not obtained or are obtained subject to conditions that are not anticipated that could require the exertion of management’s time and Centene’s resources or otherwise have an adverse effect on Centene; (ii) the risk that Centene’s stockholders do not approve the issuance of shares of Centene common stock in the WellCare Transaction; (iii) the risk that WellCare’s stockholders do not adopt the merger agreement; (iv) the possibility that certain conditions to the consummation of the WellCare Transaction will not be satisfied or completed on a timely basis and accordingly the WellCare Transaction may not be consummated on a timely basis or at all; (v) uncertainty as to the expected financial performance of the combined company following completion of the WellCare Transaction; (vi) the possibility that the expected synergies and value creation from the WellCare Transaction will not be realized, or will not be realized within the expected time period; (vii) the exertion of management’s time and Centene’s resources, and other expenses incurred and business changes required, in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for the WellCare Transaction; (viii) the risk that unexpected costs will be incurred in connection with the completion and/or integration of the WellCare Transaction or that the integration of WellCare will be more difficult or time consuming than expected; (ix) the risk that potential litigation in connection with the WellCare Transaction may affect the timing or occurrence of the WellCare Transaction or result in significant costs of defense, indemnification and liability; (x) a downgrade of the credit rating of Centene’s indebtedness, which could give rise to an obligation to redeem existing indebtedness; (xi) unexpected costs, charges or expenses resulting from the WellCare Transaction; (xii) the possibility that competing offers will be made to acquire WellCare; (xiii) the inability to retain key personnel; (xiv) disruption from the announcement, pendency and/or completion of the WellCare Transaction, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; and (xv) the risk that, following the WellCare Transaction, the combined company may not be able to effectively manage its expanded operations.
Additional factors that may cause actual results to differ materially from projections, estimates, or other forward-looking statements include, but are not limited to, the following: (i) Centene’s ability to accurately predict and effectively manage health benefits and other operating expenses and reserves; (ii) competition; (iii) membership and revenue declines or unexpected trends; (iv) changes in healthcare practices, new technologies, and advances in medicine; (v) increased healthcare costs, (vi) changes in economic, political or market conditions; (vii) changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act, collectively referred to as the Affordable Care Act (“ACA”), and any regulations enacted thereunder that may result from changing political conditions or judicial actions, including the ultimate outcome of the District Court decision in “Texas v. United States of America” regarding the constitutionality of the ACA; (viii) rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting Centene’s government businesses; (ix) Centene’s ability to adequately price products on federally facilitated and state-based Health Insurance Marketplaces; (x) tax matters; (xi) disasters or major epidemics; (xii) the outcome of legal and regulatory proceedings; (xiii) changes in expected contract start dates; (xiv) provider, state, federal and other contract changes and timing of regulatory approval of contracts; (xv) the expiration, suspension, or termination of Centene’s contracts with federal or state governments (including but not limited to Medicaid, Medicare, TRICARE or other customers); (xvi) the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; (xvii) challenges to Centene’s contract awards; (xviii) cyber-attacks or other privacy or data security incidents; (xix) the possibility that the expected synergies and value creation from acquired businesses, including, without limitation, the Fidelis Care Transaction, will not be realized, or will not be realized within the expected time period; (xx) the exertion of management’s time and Centene’s resources, and other expenses incurred and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for acquisitions, including the Fidelis Care Transaction; (xxi) disruption caused by significant completed and pending acquisitions, including, among others, the Fidelis Care Transaction, making it more difficult to maintain business and operational relationships; (xxii) the risk that unexpected costs will be incurred in connection with the completion and/or integration of acquisition transactions, including, among others, the Fidelis Care Transaction; (xxiii) changes in expected closing dates, estimated purchase price and accretion for acquisitions; (xxiv) the risk that acquired businesses, including Fidelis Care, will not be integrated successfully; (xxv) the risk that, following the Fidelis Care Transaction, Centene may not be able to effectively manage its expanded operations; (xxvi) restrictions and limitations in connection with Centene’s indebtedness; (xxvii) Centene’s ability to maintain the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; (xxviii) availability of debt and equity financing, on terms that are favorable to us; (xxxix) inflation; and (xxx) foreign currency fluctuations.
This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect Centene’s business operations, financial condition and results of operations, in Centene’s filings with the Securities and Exchange Commission (the “SEC”), including Centene’s Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, Centene cannot give assurances with respect to Centene’s future performance, including without limitation Centene’s ability to maintain adequate premium levels or Centene’s ability to control its future medical and selling, general and administrative costs.
SOURCE: Centene Corporation
Cerebreon: Debt Support Startup Close £1.5m Seed Round to Help Save UK’s Most Vulnerable
Insolvency technology startup Cerebreon close final funds in £1.5m Seed round in a bid to scale support to the UK’s most vulnerable consumers to avoid bankruptcy.
Cerebreon is working with consumers, financial institutions and insolvency practitioners, to deploy their deep learning platform to help predict and prevent insolvency ahead of time.
Gillian Doyle, Cerebreon CEO, said, “Our mission is to support the most vulnerable people in society to help them to avoid insolvency. Unsecured personal debt was measured at £3.6Bn – with the COVID-19 outbreak UK families are taking on increasing levels of debt to survive.”
She went on to say, “By supplying data, debt insight and insolvency predictions to creditors as well as the insolvency industry, we can have a direct and positive effect on financial wellbeing and ultimately survival as a result of breaks in family incomes.”
The Irish startup were selected by Accenture’s Fintech Innovation Lab to take part in the highly competitive accelerator programme which has provided Cerebreon unrivalled access to key staff in the largest financial institutions.
Former BlackRock Managing Director, Scott Condron, commented, “Cerebreon has identified how digitization and data can be used to fundamentally alter the outcomes for debt distressed consumers, allowing more to emerge from insolvency and increasing recovery rates for creditors. Tech for good in action.”
The Donegal based tech firm have partnered with tech giant Microsoft to deliver the highest levels of security to protect sensitive personal data, using Microsoft Azure.
The £1.5m seed round was led by Delta Partners and supported by HBAN/private Angels, Western Development Commission, Consilience Ventures and Growing Capital who have invested in the Irish deep learning startup to boost go to market plans and product development as the financial crisis deepens in the UK.
Kevin Monserrat, Founding Partner at Consilience Ventures, commented, “The current financial crisis makes Cerebreon one of the most important and relevant tech platforms and we are proud to support the acceleration of their support to UK consumers in debt.”
Graph Blockchain Annouces Strategic Financial Advisory Agreement with Gravitas Securities
Toronto, Ontario–(Newsfile Corp. – March 24, 2020) – Graph Blockchain Inc. (CSE: GBLC) (“Graph” or “Company“) is pleased to announce it has executed on a financial advisory agreement with Gravitas Securities (GSI) to assess future business opportunities and develop a capital markets strategy as the Company’s financial strategic advisor, while the Company moves in to creating its blockchain supported e-Commerce marketplace for the booming psychedelic and ancillary sector.
GSI will assist the Company in closing its second tranche of the Company’s previously announced non-brokered private placement (2020-02-19) to raise up to $500,000. The company previously announced it’s first tranche close of $150,000 on 03/11/2020.
“We are pleased to enter into an Advisory Agreement with GSI,” announced Christian Scovenna, President & COO of the Company. “This announcement of having an investment bank like GSI solidifies GBLC’s commitment to spearhead the Company’s direction into the e-commerce psychedelics sector while creating shareholder value. GSI has demonstrated exemplary work with public companies with an affinity for growth via M&A proves significant value it can add. We are excited to have GSI assess future business opportunities and develop a capital markets strategy as our strategic financial advisor.”
Subject to the prior approval of CSE, the Company has agreed to pay GSI a retainer fee payable for services provided for each full Calendar Month for a period of twelve months. The payment shall be comprised of (subject to approval by the Canadian Securities Exchange (the “CSE”)) $15,000 (plus applicable tax) monthly payment in stock that will be invoiced annually in full, which will be paid in common shares at a deemed price per share equal to the greater of $0.05 or the minimum price per share permitted by the CSE at the time of issuance of such shares. Subject to CSE approval, these shares will be issued to GSI immediately. GSI may be paid a cash commission on any eligible subscriptions for potential private placement(s) within the stated (12) month advisory agreement. The Company will also, as soon as reasonably practicable following closing of the Transaction and subject to compliance with the stock option plan of the Company, shareholder approval of the stock option plan and the policies of the CSE, issue stock options (each, an “Option”) to GSI entitling GSI to purchase in the aggregate up to 2.5% of the total shares issued and outstanding in the Company. The exercise price and vesting provisions, if any, for these Options will be determined by the board of directors of the Company at the time of grant in the context of the stock option plan of the Company.
The Agreement, retainer fee and Option grant will be subject to such other approval, terms and conditions as would be typical for an agreement of this nature in the Canadian market. These conditions include:
(i) a condition respecting receipt of regulatory CSE (Canadian Securities Exchange) approvals;
(ii) a condition that no material adverse change affecting GSI has occurred;
(iii) a condition that all “shares for Service” adhere to IIROC and Regulatory trading and escrowed provisions.
About Gravitas Securities Inc.
Gravitas is known for sophisticated sector expertise, tactical individuals with a commitment to excellence, global integration and innovation, and as a leading independent wealth management and capital markets firm. Gravitas provides a wide range of investment mandates and services for retail and corporate clients globally from offices in Toronto, Vancouver, and Calgary, and is represented in the United States through its FINRA representative, Gravitas Capital International, in New York and San Francisco.
About Graph Blockchain Inc.
The Company develops leading-edge private blockchain business intelligence and data management solutions that it will implement into a blockchain supported e-commerce marketplace for the sale of psychedelic and ancillary products in legal jurisdictions.
Additional Information on the Company is available at: www.graphblockchain.com
For further information, please contact:
Govinda Butcher – CEO
Phone: (416) 522-6688
Christian Scovenna – President & COO
Phone: (416) 453-4708
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. Such statements may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/53724
Announcing the Virtual Gathering of the European Tech professionals (#TCE2020VE)
The TECH Conference Europe 2020 Spring Edition becomes a hybrid conference.
We have some important updates about the upcoming TCE2020 Spring Edition.
Due to the many travel restrictions, we have decided to create a Virtual Conference which gathers Tech professionals to discuss the vital topics with which companies in Europe and around the world are dealing with.
The Virtual Conference will take place on the 9th of June and everyone is invited to join and hear how Mobility, EdTech, Artificial Intelligence, Blockchain, Fashiontech, and Fintech companies are embracing the current events and helping globally.
In order to secure your virtual seat, make sure to register here (no travel needed, you can attend from the comfort of your home or office)
PLEASE NOTE: If you are already a registered delegate of TCE Spring Edition, you don’t have to purchase a new ticket!
“As the world is sailing into uncharted waters, it is not likely that you will have the possibility to travel in the upcoming 3 months, so we are giving the chance for tech professionals, startups, investors to attend a full day of quality learning and networking from the comfort of their home” stated Zoltán Tűndik, Co-Founder and Head of Business at Hipther Agency.
The agenda of the conference has been updated and now addresses current affairs with panel discussions that revolve around the current topics which many tech industries are facing.
Among the topics of the conference, you will find discussions such as:
- Champions Of Mobility During Global Pandemic
- Fashiontech – Is The Fashion Sector Suffering Or Innovating?
- Global Consumer Sentiment During Pandemic And Boosting Essential Services
- Edtech Becomes An Essential Part Of Teaching And Providers Show Camaraderie
- Fintech, Blockchain And Fintech, Blockchain At The Forefront Of Fighting The Pandemic
More topics will be added to the agenda as the demand is high from tech companies. We are inviting all industry experts to nominate speakers here.
The speakers and moderators
Among the already confirmed speakers and moderators you can find: Jovita Gabnienė (Attorney at Law, Head of Litigation & Investigations Team at Ellex Valiunas), Stefania Barbaglio (Founder and Director at Cassiopeia Services), Erja Retzén (Senior Managing Director, Global Listing Services at Nasdaq), Filipa Neto (Innovation Principal at Farfetch), Kostandina Zafirovska (General Manager of IT Labs), Sukhi Jutla (COO & Co-founder at MarketOrders), Kamilė Kliukienė (Legal Counsel at Telia, Women Go Tech alumni), Jaka Repanšek (Media and TECH Law Expert), Rauno Parras (Director of parcel services at Itella Estonia), Marek Kopanicky (Consultant at Slovak Investment and Trade Development Agency), Gerard Martret (Co-Founder & CCO at Shotl), Vytautas Karalevičius (Co-founder at Bankera), Magith Noohukhan (Customer Engagement Evangelist at Braze), Dean Rakic (Chief Blockchain Officer at Blockcontrol Germany), Ricky Booker (Founder & CEO at Tradestreet), Slava Jefremov (CPO at Cointraffic), Vesa Perälä (CEO and Founder at Claned Group), Karim Coppola (Founder and Creative Director at VISORE LAB) and Alexander Belov (Co-Founder at Coinstelegram).
More speakers will be added along the way.
Sponsors and Partners
We are also happy to announce that IT Labs, the main sponsor of the conference has opted to support both virtual and live editions of the event.
For further inquiries about the peaking/attending/sponsoring options, make sure to send an e-mail to Andrada Bota (B2B Sales Executive at Hipther Agency).
Among the supporters of the conference, you will also find the Georgian Venture Capital Association as a strategic partner, and leading media outlets such as Coins Flare, Embassy of Blockchain, CoinPedia, TechEvents Online, AI Time Journal, Cassiopeia Services, iBlock.tv, TechieScoops, DigitalScounting.de and many more.
Visit www.virtualedition.techconferenc.eu for more details!
For media-related inquiries, please contact Alexandru Marginean (Marketing Specialist at Hipther Agency).
TECH Conference Europe (TCE) Spring Edition, BTech and NTech Awards
TCE Spring Edition will become TCE Summer and will be held on the 4th of August. More information about the topics and speakers will be announced at a later stage.
The online voting stage for BTech and NTech Awards 2020 has been stopped and will be reset in order to allow all participants to focus on different matters.
A new online voting stage will be started between 1 and 30 June. Further information will be released in the upcoming weeks.
Hipther Agency (organizers of TECH Conference Europe) press contacts:
Zoltan Tuendik, Head of Business
firstname.lastname@example.org, +40 735 559 234
Alex Marginean, Marketing Specialist
email@example.com, +40 731 394 220
Latest News8 months ago
Galaxy Digital Announces Approval of License to Underwrite Registered Public Offerings of Securities
12 months ago
The Green Organic Dutchman Receives Global Awards for New Website
Fintech12 months ago
Ally Financial Partners with Better.com to Create End-to-End Digital Mortgage Experience
Latest News8 months ago
Core Scientific launches the first AIRI-Ready Datacenter
Fintech9 months ago
PremFina Makes Final Shortlist for Hottest FinTech Startup in Europe in The Europas Awards
Latest News10 months ago
Chinsay’s Intelligent Contract Platform Enables Rio Tinto & Cargill to Complete the First Fully Digitalised Iron Ore Trade
Fintech7 months ago
Experian A/NZ acquires Australian fintech Look Who’s Charging to bolster open data offering
Fintech8 months ago
Apex Clearing Releases ‘Millennial 100’ Stock Pulse Report